The iSCAD registry (NCT04496687) has published several preliminary analyses.67–72 Lastly, the BA-SCAD (beta-blockers and antiplatelet agents in patients with SCAD; NCT04850417) randomized trial aims to assess beta-blockers and antiplatelet therapy in SCAD,73 while the Statin and Angiotensin-converting Enzyme Inhibitor on Symptoms in Patients with SCAD (SAFER-SCAD; NCT02008786) randomized trial was terminated due to slow enrolment. Here, ACE is linked to spontaneous coronary artery dissection.